Biotechnology company Cortecs, which made headlines last week with
its new oral drug for insulin, has hired Shandwick to handle its medical
and financial PR. The account covers the UK, Europe and the US.
Shandwick will replace Buchanan Communications and Brandon Harris and
Co, which handled trade and financial PR in the UK, and Keyhoe White
Savage, which handled investor relations in the US.The account is
estimated to worth at least pounds 100,000.
Cortecs made national news last week with an announcement that it has
developed oral versions of drugs including insulin. Its research means
drugs to treat diabetes and osteoporosis will no longer have to be
The market for these drugs is believed to be worth in excess of pounds
This has prompted Cortecs to review its PR, as has the fact that it is
about to transfer its primary listing from Australia to the London Stock
Exchange, which means it will make financial announcements in the UK,
rather than Australia. Shandwick’s London office will handle financial
PR, as well as investor relations and medical trade PR in Europe. The
agency’s New York office will handle investor and trade PR in the
Shandwick’s hiring follows the appointment of a full time head of
corporate communications for Cortecs. John Barrington-Carver, who has
been advising the company on a freelance, part-time basis for just over
three years, started working full time in July. He continues to work on
a freelance basis.
Shandwick used to work for another biotechnology firm - Chiroscience -
until it lost the account this summer.